Application Number 10/657,762 INFORMATION DISCLOSURE Filing Date September 8, 2003 First Named Inventor Gloria Cristalli Art Unit Unassigned -- 1623 Examiner Name Unassigned Sheet 1 of 1 Attorney Docket Number 02-0166

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
The	AA	US 2003-0078232 A1	04-24-2003	Elzein, et al.			_

Γ			FOREIGN PA	ATENT DOCUMEN	ΓS			
	Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	Т
	Pac	AL	WO 00/78777 A1	December 28, 2000	WO			
7		AM	WO 00/78778 A2 + A3	December 28, 2000	WO			
	ne	AN	WO 00/78779 A2 + A3	December 28, 2000	WO .			

~				
			OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS	
Ì	Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine,	т
	Initials*	No.	journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	1	AR	KLOTZ et al: "2-Substituted N-Ethylcarboxamidoadenosine Derivatives as High-Affinity Agonists at	ŀ
	1/0		Human A3 Adenosine Receptors", Nauny-Schmiedeberg's Archives of Pharmacology, Springer, Berlin,	, ah
	/a		DE., Vol. 360, no. 2, 1999, pages 103-108 XP000984051, ISSN: 0028-1298, compound 8, tables 1,207/13	<u> 194</u>
		AS	BARALDI et al: "Novel N6-(Substituted-phenylcarbamoyl) Adenosine-5'-Uronamides as Potent Agonist	- 1
	Ma	-	for A2 Adenosine Receptors", Journal of Medicinal Chemistry, American Chemical Society, Washington,	
	/X_		US, vol. 39, no. 3, February 1996 (1996-02), pages 802-806, XP002913657, ISSN: 0022-2623,	, I
0			conclusions on page 804, pages 803, column 2, paragraph 4; (Publ. ACS Abstr; 12/15/1995)	

Examiner Signature L. E. Crane / Came Date Considered 09/28/2004

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with rext communication to applicant.